94年1至6月开方

94年1至6月間方鍵入錯誤發生

率較高之藥品一覽表

表列為經覆核出常見之鍵入錯誤案例

藥劑部藥品異動專欄

一、新進藥品

二、藥品開方異動

三、藥品取消或暫停使用

藥品健保給付規定之相關異動

94 10 1 0940023052

7.2. Antiemetic drugs

7.2.2.neurokinin-1 receptor antagonist

aprepitant Emend 80 mg, 125

mg/cap

1.

dexametha-

sone 5-HT3

2.

5-HT3

carmustine (≥

250 mg /m2/day), cyclophos-

phamide ( > 1500 mg /m2/day),

methotrexate ≥1.2 g /m2/day

cisplatin > 50 mg/m2

94 10 1 0940019123

8.2.

8.2.8. interferon-

8.2.8.1.interferon alpha-2a

Roferon-A interferon alpha-2b

Intron A

1.

B C

B

C

C Ribavirin

HBsAg(+) HBeAg(+) ALT ( ) (ALT ≥5X)

HBsAg(+) HBeAg(+) ALT (2X ≤AL T < 5X) HBcAg

D C

( )

B

(HBsAg(+))

B

(94/10/1 ) HBsAg(+) HBeAg(-) ALT ( ) (ALT ≥2X) HBcAg D

C

( )

Anti-HCV AL T ( ) ( ) (ALT ≥2X) META VIR system F1 (

)

4 6

2.

Chronic myelogenous leukemia

Multiple myeloma

Hairy cell leukemia

T ( alpha-2A 2B type)

Kaposi's sarcoma

(low grade non-Hodgkin s lymphoma) (high tumor burden) ( LDH > 350 IU/L )

( alpha-2Atype) kasabach-Merritt

Lymphangioma

8.2.8.2.interferon alfacon-1( :Infergen)

B C

C

Ribavirin :

Anti-HCV ALT ( ) ( ) ALT ≥2X) META VIR system F1

(

)

4 6

8.2.9. peginterferon alpha-2b( :Peg-

Intron )

B C

C

Ribavirin :

Anti-HCV ALT

( )

( ) (AL T

≥2X) META VIR

system

F1

(

)

4 6

8.2.10 glatiramer acetate ( Copaxone

injection):

1.

Copaxone

2.

: 94 10 1 ( 0940025206 )

9. Antineoplastics

9.4. gemcitabine ( Gemzar)

1.

2.

3.gemcitabine paclitaxel

anthracycline

: 94 10 1 ( 0940069455 )

:

9. Antineoplastics

9.11. tegafur :

1.

2.

( U F U R

UFT)

Cisplatin

3.

2

: 94 10 1 ( 0940023310 )

9. Antineoplastics

9.21. fludarabine phosphate ( Fludara

Oral, Film Coated Tablet Fludara

Lyophilized IV Injection)

9.21.1 Fludara Oral, Film -Coated

Tablet

B- CLL

alkylating agent

9.21.2 Fludara Lyophilized IV Injection

1. B (CLL)

CLL

(LG-NHL)

(ALKYLA TING AGENT)

2.

Rai Stage /IV ( Binet C ) CLL Rai Stage I/II ( Binet

A/B ) (

)

1.

94 10 1 0940019123

10.7.

10.7.2.2.ribavirin Robatrol

Rebetol

C interferon-alfa 2a